wherein

10 R<sup>1</sup> is aryl which may have one or more suitable substituent(s), heterocyclic group or cyclo(lower)alkyl,

R<sup>2</sup> is hydrogen or amino protective group,

R<sup>3</sup> and R<sup>4</sup> are independently hydrogen, halogen, hydroxy, amimo, nitro, carboxy, protected carboxy, aryl, lower alkyl, hydroxy(lower)alkyl, amino(lower)alkyl, acyloxy(lower)alkyl, acyloxy(lower)alkyl, acyloxy(lower)alkyl, which may have one or more sultable substituent(s),

mono or di-(lower) alkylamino, acylamino, acyl group, lower alkoxy, halo(lower) alkoxy, lower alkenyloxy, lower alkoxy(lower) alkoxy, aryloxy, cyclo(lower) alkyloxy, heterocyclicoxy,

ar(lower)alkyloxy, acyloxy or acyl(lower)alkoxy,

 $R^5$  is hydrogen, lower alkyl, or aryl,

A is lower alkylene which may have one or more suitable substituent(s) or lower alkenylene,

X is 0, S, S0,  $SO_2$  or NH, and m is an integer of 0 or 1, or a salt threof.

2. A compound of claim 1, wherein  $\mathbb{R}^1$  is phenyl which may have one or more suitable substituent(s),

R<sup>2</sup> is hydrogen,

15

20

25

30

35

```
them that the three than the true that the t
```

R<sup>3</sup> is acyl(lower)alkoxy, lower alkoxy, protected carboxy, hydroxy or acyloxy, R<sup>4</sup> is hydrogen, R<sup>5</sup> is hydrogen, is lower alkylene, 5 is O, and m is an integer of 1. A compound of claim 2, wherein 3.  $R^1$  is phenyl which may have 1 or 2 suitable 10 substituent(s) selected from the group consisting of hydroxy and lower alkylsulfonylamino, R<sup>3</sup> is lower atkylcarbamoyl(lower)alkoxy, heterocycliccarbanoyl (lower) alkoxy, heterocycliccarbonyl Nower) alkoxy, 15 N-lower alkyllower alkylcarbamoyl(lower)alkoxy, hydroxy, lower alkoxy, protected carboxy, arylcarbamoyl(lower)alkoxy which may have lower 20 alkoxy or di (lower) alkylamino di-lower alkylsulfamoyloxy, N-lower alkyl-heterocyclic(lower)alkylcarbamoyl-(lower)alkoxy, N-lower alkyl-lower alkylcarbamoyl(lower)alkoxy or 25 N-lower alkyl-cyclo(lower)alkylcarbamoyl(lower)alkoxy. A compound of claim 3, wherein 4. R<sup>1</sup> is phenyl which may have hydroxy and 30 methylsulfonylamino,  $R^3$  is ethylcarbamovlmethoxy, indolylcarbamoylmethoxy, piperidinocarbonylmethoxy, 35 N-methylbutylcarbamoylmethoxy,

5

10

15

20

25

30

hydroxy,
butylcarbamoylmethoxy,
methoxy,
methoxy,
methoxycarbonyl,
ethoxy,
dimethylsulfamoyloxy,
tetrazolylcarbamoylmethoxy,
N-methylpyridylethylcarbamoylmethoxy,
methoxyphenylcarbamoylmethoxy,
thiazolylcarbamoylmethoxy,
dihydroindolylcarbonylmethoxy,
N-ethylpropylcarbamoylmethoxy,
N-methylbutylcarbamoylmethoxy,
N-methylbutylcarbamoylmethoxy,
N-ethylbutylcarbamoylmethoxy,

5. A process for preparing a compound of claim 1, or a salt thereof, which comprises,

dimethylaminophenylcarbamoylmethoxy or

N-methylcyclohexylcarbamoylmethoxy.

(i) reacting a compound [II] of the formula :

 $R^1$   $(X)_{\overline{M}}A$  CH CH  $F^5$  [II]

wherein  $R^1$ ,  $R^5$ , A, X and m are each as defined in claim 1, with a compound [III] of the formula :

$$\mathbb{R}^{2}$$

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{4}$$

wherein  $R^2$ ,  $R^3$  and  $R^4$  are each as defined in claim 1, or a salt thereof, to give a compound [I] of the formula :

$$R^{1} \xrightarrow{(X)_{m}} A \xrightarrow{OH} CH \xrightarrow{R^{2}} CH \xrightarrow{R^{1}} R^{2}$$

$$R^{1} \xrightarrow{R^{2}} R^{3}$$

$$R^{3} \qquad [1]$$

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , A, X and m are each as defined in claim 1, or a salt thereof, or

(ii) subjecting a compound [Ia] of the formula:

$$\begin{array}{c|c}
R^1 \xrightarrow{(X)_{\overline{M}}} R \xrightarrow{CH-CH-N} R^3
\end{array}$$
[Ia]

wherein  $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , A, X and m are each as defined in claim 1, and  $R_a^2$  is amino protective group, or a salt thereof, to elimination reaction of the amino protective group, to give a compound [Ib] of the formula:

wherein  $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^5$ , A, X and m are each as defined in claim 1, or a salt thereof.

6. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a

5

10

15

25

20

30

pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers or excipients.

- 7. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a
- A compound of claim or a pharmaceutically acceptable 8. thereof for use as a medicament.
- A method for the prophylactic and/or the therapeutic treatment of pollakiuria or urinary incontinence which comprises administering a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

5

10

15

20